Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

DAN-222

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Dantari

Drug class:

Topoisomerase I inhibitor

Related drugs:

irinotecan liposomal (0)

topotecan episcleral (0)

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

datopotamab deruxtecan (11)

HRA00129-C004 (3)

sacituzumab tirumotecan (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

PF-08046044 (1)

rinatabart sesutecan (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

›

BRCA wild-type	HER2 Negative Breast Cancer	BRCA wild-type	HER2 Negative Breast Cancer	DAN-222 Sensitive: C3 – Early Trials DAN-222 Sensitive : C3	DAN-222 Sensitive: C3 – Early Trials DAN-222 Sensitive : C3
BRCA wild-type	HER2 Negative Breast Cancer	BRCA wild-type	HER2 Negative Breast Cancer	niraparib + DAN-222 Sensitive: C3 – Early Trials niraparib + DAN-222 Sensitive : C3	niraparib + DAN-222 Sensitive: C3 – Early Trials niraparib + DAN-222 Sensitive : C3